733 related articles for article (PubMed ID: 29480190)
21. ALS/FTD phenotype in two Sardinian families carrying both C9ORF72 and TARDBP mutations.
Chiò A; Restagno G; Brunetti M; Ossola I; Calvo A; Canosa A; Moglia C; Floris G; Tacconi P; Marrosu F; Marrosu MG; Murru MR; Majounie E; Renton AE; Abramzon Y; Pugliatti M; Sotgiu MA; Traynor BJ; Borghero G;
J Neurol Neurosurg Psychiatry; 2012 Jul; 83(7):730-3. PubMed ID: 22550220
[TBL] [Abstract][Full Text] [Related]
22. Analysis of C9orf72 in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Argentina.
Itzcovich T; Xi Z; Martinetto H; Chrem-Méndez P; Russo MJ; de Ambrosi B; Uchitel OD; Nogués M; Silva E; Rojas G; Bagnatti P; Amengual A; Campos J; Rogaeva E; St George-Hyslop P; Allegri R; Sevlever G; Surace EI
Neurobiol Aging; 2016 Apr; 40():192.e13-192.e15. PubMed ID: 26925510
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneous brain FDG-PET metabolic patterns in patients with C9orf72 mutation.
Castelnovo V; Caminiti SP; Riva N; Magnani G; Silani V; Perani D
Neurol Sci; 2019 Mar; 40(3):515-521. PubMed ID: 30554355
[TBL] [Abstract][Full Text] [Related]
24. ALS-FTD complex disorder due to C9ORF72 gene mutation: description of first Polish family.
Siuda J; Lewicka T; Bujak M; Opala G; Golenia A; Slowik A; van Blitterswijk M; Baker M; Ertekin-Taner N; Wszolek ZK; Rademakers R
Eur Neurol; 2014; 72(1-2):64-71. PubMed ID: 24861139
[TBL] [Abstract][Full Text] [Related]
25. Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population.
Umoh ME; Fournier C; Li Y; Polak M; Shaw L; Landers JE; Hu W; Gearing M; Glass JD
Neurology; 2016 Sep; 87(10):1024-30. PubMed ID: 27488601
[TBL] [Abstract][Full Text] [Related]
26. Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD.
Starr A; Sattler R
Brain Res; 2018 Aug; 1693(Pt A):98-108. PubMed ID: 29453960
[TBL] [Abstract][Full Text] [Related]
27. Predicting Development of Amyotrophic Lateral Sclerosis in Frontotemporal Dementia.
Van Langenhove T; Piguet O; Burrell JR; Leyton C; Foxe D; Abela M; Bartley L; Kim WS; Jary E; Huang Y; Dobson-Stone C; Kwok JB; Halliday GM; Hodges JR
J Alzheimers Dis; 2017; 58(1):163-170. PubMed ID: 28387671
[TBL] [Abstract][Full Text] [Related]
28. Tale of two diseases: amyotrophic lateral sclerosis and frontotemporal dementia.
Verma A
Neurol India; 2014; 62(4):347-51. PubMed ID: 25237937
[TBL] [Abstract][Full Text] [Related]
29. ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD.
Moore S; Alsop E; Lorenzini I; Starr A; Rabichow BE; Mendez E; Levy JL; Burciu C; Reiman R; Chew J; Belzil VV; W Dickson D; Robertson J; Staats KA; Ichida JK; Petrucelli L; Van Keuren-Jensen K; Sattler R
Acta Neuropathol; 2019 Jul; 138(1):49-65. PubMed ID: 30945056
[TBL] [Abstract][Full Text] [Related]
30. C9orf72 hexanucleotide repeat expansions as the causative mutation for chromosome 9p21-linked amyotrophic lateral sclerosis and frontotemporal dementia.
Daoud H; Suhail H; Sabbagh M; Belzil V; Szuto A; Dionne-Laporte A; Khoris J; Camu W; Salachas F; Meininger V; Mathieu J; Strong M; Dion PA; Rouleau GA
Arch Neurol; 2012 Sep; 69(9):1159-63. PubMed ID: 22964911
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia.
Dols-Icardo O; García-Redondo A; Rojas-García R; Sánchez-Valle R; Noguera A; Gómez-Tortosa E; Pastor P; Hernández I; Esteban-Pérez J; Suárez-Calvet M; Antón-Aguirre S; Amer G; Ortega-Cubero S; Blesa R; Fortea J; Alcolea D; Capdevila A; Antonell A; Lladó A; Muñoz-Blanco JL; Mora JS; Galán-Dávila L; Rodríguez De Rivera FJ; Lleó A; Clarimón J
Hum Mol Genet; 2014 Feb; 23(3):749-54. PubMed ID: 24057670
[TBL] [Abstract][Full Text] [Related]
32. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?
van Blitterswijk M; DeJesus-Hernandez M; Rademakers R
Curr Opin Neurol; 2012 Dec; 25(6):689-700. PubMed ID: 23160421
[TBL] [Abstract][Full Text] [Related]
33. C9ORF72 hexanucleotide repeat expansion: From ALS and FTD to a broader pathogenic role?
Sellier C; Corcia P; Vourc'h P; Dupuis L
Rev Neurol (Paris); 2024 May; 180(5):417-428. PubMed ID: 38609750
[TBL] [Abstract][Full Text] [Related]
34. Stable transgenic C9orf72 zebrafish model key aspects of the ALS/FTD phenotype and reveal novel pathological features.
Shaw MP; Higginbottom A; McGown A; Castelli LM; James E; Hautbergue GM; Shaw PJ; Ramesh TM
Acta Neuropathol Commun; 2018 Nov; 6(1):125. PubMed ID: 30454072
[TBL] [Abstract][Full Text] [Related]
35. Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features.
Sha SJ; Takada LT; Rankin KP; Yokoyama JS; Rutherford NJ; Fong JC; Khan B; Karydas A; Baker MC; DeJesus-Hernandez M; Pribadi M; Coppola G; Geschwind DH; Rademakers R; Lee SE; Seeley W; Miller BL; Boxer AL
Neurology; 2012 Sep; 79(10):1002-11. PubMed ID: 22875087
[TBL] [Abstract][Full Text] [Related]
36. Targeted next-generation sequencing study in familial ALS-FTD Portuguese patients negative for C9orf72 HRE.
Gromicho M; Coutinho AM; Pronto-Laborinho AC; Raposeiro R; Tavares J; Antunes D; de Carvalho M
J Neurol; 2020 Dec; 267(12):3578-3592. PubMed ID: 32638105
[TBL] [Abstract][Full Text] [Related]
37. There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS.
Gitler AD; Tsuiji H
Brain Res; 2016 Sep; 1647():19-29. PubMed ID: 27059391
[TBL] [Abstract][Full Text] [Related]
38. Age-related penetrance of the C9orf72 repeat expansion.
Murphy NA; Arthur KC; Tienari PJ; Houlden H; Chiò A; Traynor BJ
Sci Rep; 2017 May; 7(1):2116. PubMed ID: 28522837
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a family with c9FTD/ALS associated with the GGGGCC repeat expansion in C9ORF72.
Savica R; Adeli A; Vemuri P; Knopman DS; Dejesus-Hernandez M; Rademakers R; Fields JA; Whitwell J; Jack CR; Lowe V; Petersen RC; Boeve BF
Arch Neurol; 2012 Sep; 69(9):1164-9. PubMed ID: 22637471
[TBL] [Abstract][Full Text] [Related]
40. C9orf72 repeat expansions are restricted to the ALS-FTD spectrum.
Ticozzi N; Tiloca C; Calini D; Gagliardi S; Altieri A; Colombrita C; Cereda C; Ratti A; Pezzoli G; Borroni B; Goldwurm S; Padovani A; Silani V
Neurobiol Aging; 2014 Apr; 35(4):936.e13-7. PubMed ID: 24169076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
